drugset / Trial / NCT01850823

Clinical Equivalence Study of Mometasone Nasal Spray

NCT01850823

Phase 3 Completed 880 enrolled Actavis Inc. Watson Laboratories, Inc. · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Site Study to Compare the Clinical Equivalence of Mometasone Nasal Spray (Watson Laboratories, Inc) with NASONEX® Nasal Spray (Schering Corporation) in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

Timeline

Start
2013-02
Primary completion
2013-12
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Mometasone Other / unclassified Intranasal